Expression And Clinical Significance Of TIF1? In Prostate Cancer

Objective:Transcriptional Intermediary Factor1?(TIF1?),as a research hotspot in recent years,has been found to be highly expressed in breast cancer,ovarian cancer,prostate cancer,pancreatic cancer.The expression of this protein has a clear correlation with the clinical stage of related malignant tumors and the degree of differentiation of tumor tissues.In this paper,through the measurement of TIF1?protein in benign prostatic hyperplasia and prostate cancer tissue,combined with clinical data to explore the expression of TIF1?protein in prostate cancer and benign prostatic hyperplasia and its relationship with the risk factors of prostate cancer,age,lymph node metastasis,and five-year survival rate.In the future,it will provide a theoretical basis for the prognosis analysis of prostate cancer and the selection of prostate cancer treatment targets.Methods:Immunohistochemical method(SP method)was used to detect the expression of TIF1?protein in 49 cases of benign prostatic hyperplasia tissue paraffin specimens and 49 cases of prostate cancer tissue paraffin specimens,and to further analyze the relationship between its expression and prostate cancer Gleason score.Then,Western blot was used to quantitatively determine the TIF1?protein in 51 fresh specimens of prostate cancer tissues and 51 fresh specimens of prostate hyperplasia tissues.To analyze the relationship between TIF1?protein and the age,Gleason score,clinical stage,preoperative PSA level,and lymph node metastasis of prostate cancer patients.Statistical processing was performed using SPSS23.0 software,measurement data is analyzed by t test,counting data comparison was performed using?2 test or Fisher's exact probability method,P<0.05 was considered statistically significant,and the graph was drawn using GraphPad Prism 8.Results:1.Immunohistochemical results showed that the positive expression rate of TIF1?protein in prostate cancer tissue was 79.60%(39/49),which was higher than 12.2%(6/49)in benign prostatic hyperplasia tissue.The difference between the two was statistically significant(P<0.05).The expression of TIF1?protein in prostate cancer tissue is significantly higher than that in prostate hyperplasia tissue.2.The positive expression rate of TIF1?protein in prostate cancer tissues of low-and middle-risk groups was 63.64%(14/22),and its positive expression rate was 92.59%(25/27)in high-risk groups.Compared with its expression in the low-and middle-risk group,the difference between the two was statistically significant(P=0.032).3.TIF1?protein expression positive group and negative group,the 5-year overall survival rate,through the Log-Rank test,X~2=0.061,P=0.805,there was no significant statistical difference between the two groups.4.Western blot results showed that the expression level of TIF1?protein in prostate cancer tissue was(2.94±0.97),and that in prostate hyperplasia tissue was(0.52±0.48).The expression of this protein in prostate cancer tissue was significantly higher than that in prostate hyperplasia tissue.The difference was statistically significant(P<0.05).5.The expression of TIF1?protein is closely related to the preoperative PSA level,Gleason score,and clinical stage of prostate cancer.In addition,the expression of TIF1?protein has no significant correlation with the age of the patient and whether lymph node metastasis occurs(P>0.05).Conclusion:1.The expression of TIF1?protein in prostate cancer tissue is significantly higher than that in prostate hyperplasia tissues,suggesting that the abnormal expression of TIF1?protein is closely related to the occurrence of prostate cancer.This can provide effective theoretical evidence support for further clinical application of prognostic analysis of prostate cancer patients and selection of prostate cancer treatment targets.2.The expression level of TIF1?protein in prostate cancer was positively correlated with the preoperative PSA level,clinical stage and Glesaon score.There is no obvious correlation with the patient's age and lymph node metastasis.3.The expression of TIF1?protein has no significant correlation with the 5-year survival rate of prostate cancer patients.